Digestion of starch requires activities provided by 6 interactive small intestinal enzymes. Two of these are luminal endoglucosidases named a-amylases. Four are exo-glucosidases bound to the luminal surface of enterocytes. These mucosal activities were identified as 4 different maltases. Two maltase activities were associated with sucrase-isomaltase. Two remaining maltases, lacking other identifying activities, were named maltase-glucoamylase. These 4 activities are better described as a-glucosidases because they digest all linear starch oligosaccharides to glucose. Because confusion persists about the relative roles of these 6 enzymes, we ablated maltase-glucoamylase gene expression by homologous recombination in Sv/129 mice. We assayed the a-glucogenic activities of the jejunal mucosa with and without added recombinant pancreatic a-amylase, using a range of food starch substrates. Compared with wild-type mucosa, null mucosa or a-amylase alone had little a-glucogenic activity. a-Amylase amplified wild-type and null mucosal a-glucogenesis. a-Amylase amplification was most potent against amylose and model resistant starches but was inactive against its final product limit-dextrin and its constituent glucosides. Both sucrase-isomaltase and maltase-glucoamylase were active with limit-dextrin substrate. These mucosal assays were corroborated by a 13 C-limit-dextrin breath test. In conclusion, the global effect of maltase-glucoamylase ablation was a slowing of rates of mucosal a-glucogenesis. Maltase-glucoamylase determined rates of digestion of starch in normal mice and a-amylase served as an amplifier for mucosal starch digestion.
Introduction
Food starches constitute a major source of energy in the diet of many mammalian species, including humans. Starches exist as semicrystalline energy storage granules in all plants (1) . The granules are most concentrated in reproductive tissues, to which photosynthetically produced sugars are transported and stored as large a-glucose polymers. The structural and chemical composition of starch granules varies with each plant species and within each tissue (1) . The large range of starch compositions in the plant kingdom suggests that mammalian carbohydrate digestion must be equally adaptive between and within each animal species and be as varied as the range of plants within the usual diet. The digestibility of a-glucose bonds of starch granules by mammals is in contrast to the universal resistance of the b-glucose bonds of plant structures. This suggests a-glucose bond specificity throughout the diverse digestive processes of the animal kingdom. The collective interaction of the plant and animal kingdoms is recognized in the carbon cycle, where the CO 2 produced by animals is fixed by photosynthesis in plants and returned as carbohydrates to fuel animal energy needs.
The digestion of starch to free glucose is called a-glucogenesis. This process varies in each species but generally uses a consortium of 6 a-glucogenic enzymes. Two enzymes are secreted salivary and pancreatic luminal activities called a-amylases (AMY), 11 which hydrolyze internal a-1,4 glucose bonds of linear starch polymers and polymer branches (2) . The genes for the aamylases, which are 98% homologous, are located within the same chromosomal locus. The gene has been found in all Coelomata sequenced. The mammalian AMY enzymes and their mechanisms of action are well understood (2) (3) (4) (5) (6) (7) . Additional enzyme activities are bound to the luminal surface of small intestinal enterocytes (8) (9) (10) (11) (12) (13) . These activities were first described as maltases, to distinguish the activities from AMY, which poorly digests maltose (14) (15) (16) (17) . Subsequent investigations distinguished 4 different maltase activities (11) (12) (13) . Two activities were associated with the activities of a twined catalytic complex named sucrase-isomaltase (SI) (18) (19) (20) (21) (22) . Two other activities were not associated with any identifying substrate specificities and were named maltase-glucoamylase (MGAM) (14) (15) (16) (17) . It has become recognized that these 4 maltase activities extend to other linear glucosides of infinite length and are thus better described as a-glucosidases (18) (19) (20) (21) (22) . All 4 hydrolyze nonreducing terminal a-1,4 glucose bonds. The membrane bound catalytic unit of SI also has a a-1,6 activity that can hydrolyze branched starches (20) . There is no amino acid sequence homology between the a-glucosidases and the AMY, but there is about a 60% homology within the tandem terminals and between the SI and MGAM complexes. These amino acid sequences also showed that the 2 enzymes have homology with Family 31 Gluco-hydrolases, found in nearly all eukaryotic organisms reported to date (14) (15) (16) . Similarity of sequences makes it difficult to discriminate between SI and MGAM complexes at the genomic level, but the expression of the genes from 2 different chromosomes is characteristic. SI is only expressed in the intestine but 3# sequences of MGAM and its activities have been detected in many tissues (14) .
The apparent redundancies of the a-glucosidases have resulted in confusion about their individual roles. As an example, the in vitro hydrolysis of starch substrates by AMY produces some free glucose; this has led some to classify the enzyme as the major a-glucosidase (2). Others have thought that the mucosal a-glucosidases serve only as a backup for the luminal AMY enzymes (2) . To resolve this lingering uncertainty, we ablated the MGAM gene (called Mgam in mice) to determine its function and whether the residual SI activity (called Si in mice) is in fact redundant. The absence of Mgam allowed the determination of the function of Si activities on starch digestion to glucose. The availability of human recombinant pancreatic amylase (rhpAMY) permitted clarification of its role in starch digestion (6, 7) . The a-glucogenic activities of the Mgam null and wild-type (WT) mucosa were assayed in vitro with a variety of starches and starch hydrolysates. The mucosal assay results were confirmed in vivo. Because of the potential roles of starch digestion on glucose-driven disorders such as type II diabetes, we also tested the effects of the a-glucosidase inhibitor acarbose in vitro (23) .
Materials and Methods
Mutation of Mgam by homologous recombination. Three genomic clones were identified in a mouse library screened with 5# PCR primer sets previously used in cloning and sequencing the human MGAM cDNA (15) . Sequencing of the mouse genomic clones revealed a conserved Mgam exon 2. A targeting vector containing the Lac Z -MC1neo selection marker and the flanking thymidine kinase genes was designed to replace parts of exon 2 ( Figure 1) . The construct was electrophorated into strain Sv/129 stem cells. Three positive stem cell clones that were identified by Southern analysis using 3#or 5# external probes were implanted in prepared foster dams. The F1 generation was back-crossed with the same Sv/129 strain of mice and heterozygotes were identified by Southern analysis. After germ line transmission, the Mgam genotypes were identified by quantitative PCR (qPCR) of tail DNA. The control strains of mice were purchased from Jackson Laboratory. All mouse experiments were approved under the Baylor College of Medicine Institutional Animal Care and Use Committee protocol AN-1577.
Genotyping of mice by qPCR. The Mgam genotypes were confirmed by real time-PCR of tail DNA with primer sets that shared probes and reverse primers, but had different forward primers in exon 2 or in Lac-Z of the cassette (Supplemental Table 1 ). qPCR were performed in a ABI 7900HT instrument (Applied Biosystems) with TaqMan Universal PCR Master Mix, 900 nmol/L forward and reverse primers, 100 nmol/L TaqMan Probe, and 50 ng tail-derived DNA. After 40 cycles of 2 min UNG incubation at 50°C, 10 min activation at 95°C, and PCR at 95°C for 15 s, the reaction was held at 60°C for 1 min. Heterozygous mice served as positive controls and no template or no RT reactions served as negative controls. The breeding genotypes were confirmed to be accurate by qPCR in 44 generation 10 mice.
Phenotyping of mice by Western blots and histochemistry. Mgam is internally duplicated with catalytic sites at both the N-terminal and C-terminal (14, 15) . A peptide was designed from translated Mgam nucleotide sequences to be specific for exon 25, located in the trefoil region at the beginning of the C-terminus. Peptide FFTREEERIDC (located at Mgam-893) was used for immunizing rabbits. The peptide was conjugated to KLH and used with Freund's adjuvant to immunize rabbit 14807. Antibody (Ab) titers were tested after 77 d and were .20,000 against the immunizing peptide. The resulting 14807 Ab were then immunopurified and used to resolve Western blot of Mgam null and WT jejunum homogenates that were developed by chemoluminiscence. Monoclonal Ab (mAb) DBB 2/68 against N-terminal subunit of rat Mgam confirmed (24, 25) the results obtained with the polyclonal Ab. After centrifuging jejunal homogenates for 100,000 3 g for 60 min, the 14807 Ab and mAb DBB 2/68 were used to test for presence of soluble Mgam in supernatants (25) .
The homologous recombination cassette contained the E. coli b-glucosidase knock-in gene. Localization of the expressed b-glucosidase, driven by the intact Mgam promoter, was evaluated in OCT-embedded frozen jejunal sections of Mgam null mice using 5-bromo-4-chloro-3-indolyl a-D-galactopyranoside (X-gal, Sigma-Aldrich) substrate. 11 Abbreviations used: AMY, a-amylase; Ab, antibody; BBA, barley b-Amylase; CBA/CaJ, jejunal homogenate with congenital deficiencies of Mgam and Si; DOB, 13 CO 2 -delta over baseline; G2, maltose; G3, maltotriose; G4, maltotetraose; G5, maltopentose; Ki, inhibitory constant; Km, Michaelis constant; LD, corn a-limit-dextrin; MA, maltogenic a-amylase; mAb, monoclonal antibody; MD, corn maltodextrin; Mgam, mouse maltase-glucoamylase; MGAM, human maltase-glucoamylase; O2-5, glucosides from 2 to 5 glucose units long; qPCR, quantitative PCR; rhpAMY, recombinant human pancreatic amylase; Si, mouse sucrase-isomaltase; SI, human sucrase-isomaltase; TG, Aspergillus transglucosidase; TGO, Tris glucose-oxidase; Vmax, maximum rate of reaction; WT, wild-type; WX, waxy cornstarch. Starch digestion and oxidation to CO 2 . Starch digesting phenotypes were investigated in 4 null and 4 WT mice by assaying the extent of conversion of fed 13 C-starch substrate to 13 CO 2 levels in breath. Universally labeled 13 C-starch of algal source (Sigma-Aldrich) was exhaustively digested with porcine AMY (Type VI-B, Sigma-Aldrich) to make 13 C-labeled limit dextrin (LD), which is insensitive to further luminal digestion. The soluble fraction of 13 C-LD was freeze-dried and used for testing starch digestion. Based upon exhaustive AMG (Megazyme International) digestion followed by the glucose oxidase reaction, the 13 C-LD solution contained 3.48 6 0.12 g/L glucose equivalents, of which only 0.21 6 0.01 g/L (6%) was free glucose. Genotyped mice were fed a low 13 C-nonpurified diet (Harlan Teklad; TD.0689) for 2 wk before the experiment. The mice were then fasted overnight and placed in a 0.24 L glass breath collection chamber. Airflow to the chamber was 0.24 L/min. The airflow was interrupted for 7.5 min and then restarted for 2.5 min. The initial 0.24 L of effluent air was collected into a CO 2 impervious bag and the chamber was washed out. The collected effluent samples were analyzed with a POCone IR spectrophotometer (Otsuka Electronics) for total CO 2 Dahlqvist a-glucogenesis assays. The sucrase, maltase, and lactase assays were those described by Dahlqvist (10, 26) at 16-mol/L concentrations and 60-min incubations at 37°C. The a-glucosidase assay was a modification previously described (27) with 20 g/L maltodextrin (MD) used as substrate. Activity was reported as international enzyme units (U/g protein; 1 U ¼ 1 mmol of glucose released per minute of reaction).
Measures of catalytic properties. Because Dahlqvist assay measurements of human disaccharidase activities fail to differentiate the different maltase activities (16), we took measurements of the kinetic parameters of Michaelis constants (Km), and maximum rate of reaction (Vmax) of jejunal mucosa on maltose, sucrose, isomaltose, and palatinose substrates using the Tris glucose-oxidase (TGO) technique adapted to 96-well plates (28) . Briefly, 10 mL of jejunal mucosa scraping homogenates were mixed with 10 mL of substrate solutions at concentrations ranging from 0.1 to 50 mmol/L for maltose and isomaltose, 1.1 to 100 mmol/L for sucrose, or 0.5 to 25 mmol/L for palatinose and incubated at 37°C for 30 min for maltase and isomaltase activities, or 60 min for sucrase and palatinase activities. To determine the inhibitory constants (Ki) of acarbose, before the incubation period, 10 mL of acarbose (Toronto Research Chemicals) solutions were added to the reaction mixtures to attain final concentrations of 1, 10, 100, and 1000 mmol/L . After incubations, 200 mL of TGO reagent were added to each well, the plates were incubated for an additional 60 min at 37°C, and then the OD at 450 nm of each well was measured in a SpectraMax190 microplate spectrophotometer (Molecular Devices). A standard curve of glucose concentration was run in parallel for each assay. Protein concentration in homogenates was measured by the Bradford method. Activities are reported as international units of activity per mg of protein.
Kinetic a-glucogenesis assay. Soluble substrates (maltose, isomaltose, MD, and LD) were dissolved at 5 g/L in PBS (10 mmol/L phosphates pH 6.8 with 150 mmol/L NaCl). Insoluble starches were wetted and then dissolved in DMSO at 10 g/L, by heating at 90°C for 30 min. Solubilized starches were precipitated with 4 volumes of 100% ethanol, sedimented by centrifugation, dried, and dissolved in warm (40°C) PBS at 5 g/L. Real-time glucose release was measured by a modification of the assay described above (28) . Phosphate glucose-oxidase developing reagent (190 mL containing 150 U/L of glucose oxidase, 750 U/L of horseradish peroxidase, 0.2% Triton 3100, and 50 mg/L of O-dianosidine-HCl, all in PBS), were placed in each well. Next, 10 mL of individual substrate were added to the wells (240 mg/L final concentration), the mixtures were preincubated for 10 min at 37°C, and then 10 mL of enzyme preparations were added to each well. OD at 450 nm was measured in the microplate spectrophotometer at 37°C at 2 min intervals with a 3 s shaking before each reading. rhpAMY (6,7) was added in a volume of 10 mL to obtain a final concentration of 1.8 mg/L. Solubilized mouse jejunal lysates were prepared by mixing 1 volume of a 10% sodium deoxycholate with 10% Nonidet P40 solution and 10 volumes of homogenate (100 g/L in PBS). After 1 h mixing by rotation at 4°C, lysates were centrifuged at 15,600 3 g and supernatants recovered and diluted 1:10 with PBS. For glucogenic assays, 10 mL of diluted lysate supernatants were added to appropriate wells. All measurements were in triplicate. Blanks for substrate and enzyme preparations were included in each assay.
Maltodextrin and a-limit-dextrin characterizations. The food grade MD used (Polycose, Ross Laboratories) was manufactured by partial fungal AMY a-1,4-digestion of cornstarch (1) . The composition of MD, as determined by MALDI-TOF analysis before and after digestion with porcine pancreatic AMY, is described elsewhere (16) . Data of mass fraction and MW for each oligomer, determined by MALDI-TOF analysis, were used to calculate the mean MW of MD. Reagent grades of maltose (G2), maltotriose (G3), maltotetraose (G4), maltopentose (G5), sucrose, palatinose, whole starch, amylopectin, and amylose substrates were purchased from Sigma-Aldrich.
Resistant starch production. The methods of production and properties of resistant starches from normal cornstarch are fully described elsewhere (29) . Normal cornstarch was a gift from Tate and Lyle, Inc. Statistics. Differences in the rate of breath release of 13 CO 2 between strains were determined by ANOVA by the General Lineal Model, using strains as classifying factor and time as a covariate. Pairs of data (strain 3 time) with significant differences were determined by pairwise comparisons by the simultaneous test of Dunnett's (family error rate ¼ 0.01) with WT mice as the control group. One-way ANOVA and Dunnett's test were used to determine differences in the levels of enzymatic activities measured by Dahlqvist's method between WT and heterozygous and null mice, with WT as a control group. Fisher's test (individual error rate ¼ 0.01) was used to identify differences between heterozygous and null mice. Apparent Vmax, Km, and, when necessary, Ki values were calculated using nonlinear regression with the Marquardt-Levenberg algorithm, and models were adjusted to a single substrate Michaelis-Menten, a competitive inhibition, or to substrate inhibition kinetics. Differences between calculated kinetic parameters of the respective strains were determined pairwise by the Z test. Rates of reaction for real time glucogenesis assays were calculated under steady-state conditions by linear regression, during intervals from 10 to 30 min of reaction. Indices of digestion for different starches and derived substrates were calculated as the ratio of the rates of reaction at steady state, divided by the isomaltase activity observed after 60 min incubations for each enzyme mixture. Indices of digestion were analyzed by ANOVA and the General Lineal Model, with time as a covariate and enzyme mixture and/or substrate as classifying factors. Differences between indexes for each enzyme mixture and starch product were determined by 1-way ANOVA and Tukey's test (family error rate ¼ 0.01). Statistical significance was considered at P , 0.05, unless otherwise noted. 
Results

Confirmation of Mgam
Real time RT/PCR. The ablation of Mgam exon 2 in Mgam null mice was confirmed by qPCR from tail DNA. These mice with identified genotypes were used to breed experimental mice. After 10 generations of breeding, 44 random current-generation experimental mice were experimentally genotyped, and complete agreement was documented between the breeding and qPCR genotypes. (Fig. 2) . This finding was confirmed by Western blot, using an anti-rat mAb recognizing the Mgam N-terminal subunit, and revealed deletion of the Mgam null mouse C-terminal as well as N-terminal subunits (25) 
Western blot
Frozen sections from Mgam null jejunal mucosa showed b-glucosidase activity within enterocytes of the midportion of jejunal and ileal villous structures. There was no staining of control WT mouse mucosa (25) .
Starch digesting phenotype. The response of mouse breath 13 CO 2 concentrations to a 13 C-starch load varied according to Mgam genotype (Fig. 3) . WT mice reached a mean enrichment of ;230 DOB at 60 min, whereas the null mice reached a plateau at 100 DOB after 30 min, following the 13 C-LD bolus feeding.
cDNA sequencing. The sequences of the Mgam null mice differed from the WT mice at the second exon, which was spliced out of the null mouse (GenBank accession numbers: Mgam WT: AY229885; Mgam Null: AY229886).
Dahlqvist assay mucosal enzyme activities. Mucosal homogenates from jejunum and ileum were assayed by the Dahlqvist method for total production of free glucose. The in vitro jejunal enzyme activity assays ( Table 1) for 3 a-glucosidase substrates (MD, maltose, and amylose) were reduced in Mgam null but not in heterozygous mice. All 3 of these hydrolytic activities in homogenates were significantly reduced by ANOVA analysis in the jejunum, and maltose activity was also reduced in the ileum of Mgam null mice ( Table 1) . Hydrolysis of sucrose and lactose was significantly increased by ANOVA analysis in the jejunum and ileum of the null mice. Assays with ileal mucosa (Table 1 ) demonstrated similar differences in a-glucosidase activities in Mgam null, heterozygous, and WT mice to those observed in jejunum. In summary, a-glucosidases showed an ;50% reduction in the Mgam null jejunal homogenates, and sucrase and lactase activities were increased. The Mgam heterozygous null mouse had brush border enzyme activity levels identical to the WT mouse.
Kinetics of activities of a-glucogenic substrates. The enzyme kinetic parameters of the Mgam WT, null, and jejunal homogenates with congenital deficiencies of Mgam and Si (CBA/ CaJ) mouse strains (Jackson Laboratory) are summarized in Table 2 . The Km for maltose substrate was increased 5 to 10 times in the Mgam null and CBA/CaJ mouse jejunum, indicating that it was caused only by Si subunits and that this was reflected by a .60% reduction of the corresponding Vmax in the deficient strains. In contrast, the Km for sucrose, isomaltose, and palatinose hydrolysis were comparable across all 3 genotypes. However, the Vmax for isomaltase activities were increased by 50% in the Mgam null and CBA/CaJ mouse jejunums. Interestingly, although sucrase activity was also increased by 50% in Null mice, in CBA/CaJ mice it was decreased ;50%, with respect to WT mice. These observations suggest that the synthesis of Si molecules is enhanced as a compensatory effect of the Mgam deficiency. The low sucrase activity in CBA/CaJ mice was expected, because we previously found a faster rate of inactivation of the sucrase subunit in this strain (28) .
Rates of a-glucogenesis. The rates of a-glucogenesis of null were compared with the WT mouse jejunal homogenates (Fig.  4) . As expected, the rate of glucose production from maltose substrate was ;2000% greater in WT than null jejunum mice, but rates of a-glucogenesis from isomaltose substrate were identical (Fig. 4) . This conservation of isomaltase activity in the null mice led to the normalization of further assays to the rate of isomaltose hydrolysis. Because maltose is not a substrate for rhpAMY hydrolysis, MD was used as substrate in the a-glucogenic assay to determine the interactive effect of rhpAMY with the mucosal homogenates. The direct a-glucogenic effect of rhpAMY on the MD substrate was very low (Fig. 5) . The a-glucogenic activity on MD of the WT jejunal homogenate was ;24 times higher than that of the Mgam null mouse. The addition of rhpAMY to the mucosal homogenate amplifies the activity of the null and WT jejunal homogenates 1.5-to 3-fold (Fig. 5) .
As mentioned earlier, the composition of starches is highly variable. Therefore, the understanding of starch digestion requires the testing of a broader range of food starch substrates ( Table 3) . Under our kinetic a-glucogenic assay conditions, the activity of rhpAMY was negligible with all studied substrates in relation to the activity of intestinal mucosal homogenates of WT (,5% of WT) mice, containing both Mgam and Si, or null mice, containing Si alone (Table 3) . Thus, human pancreatic amylase can not be considered an intestinal a-glucogenic enzyme when digesting typical maltogenic substrates present in a regular human diet, such as normal cornstarch, MD, amylase, or amylopectin. We detected a important, but small, a-glucogenic activity of rhpAMY only against our synthetic LD (O2-5) and MD ( Table 3 ), suggesting that this activity may be in part due to the transglucosilating activity described previously for this enzyme, using the same short glucose oligomers contained in oligomers of 2 to 5 glucose residues (O2-5) (2).
a-Glucogenic activity of null mice intestinal mucosa homogenates containing only Si had substantially impaired digestion of all starches, showing measurable indexes of glucose production only for MD, porcine pancreatic AMY digested LD. or the synthetic LD containing O2-5 (Table 3) . However, in the presence of rhpAMY, null mice intestinal mucosa showed substantial a-glucogenic activity with all assayed substrates, indicating that glucose production by Si is inefficient with long-chain glucosides and becomes relevant only in the presence of short glucose oligomers. A synergic effect of rhpAMY on Si activities was evident with substrates that were susceptible to attack by rhpAMY (long linear chains such as amylose) and releasing a high concentration of unbranched products, whereas the lowest effect was observed with substrates with low susceptibility to rhpAMY digestion and containing a high concentration of branched molecules (such as MD or LD) (32) (33) (34) . These observations support the suggestion that short glucose oligomers require Si for efficient glucose production.
In contrast to null mice, WT intestinal mucosa homogenates containing Mgam and Si displayed substantial a-glucogenic activity with all assayed substrates and in the absence of rhpAMY ( Table 3) . As expected, O2-5 was the most susceptible substrate for digestion by WT mucosa, whereas amylose was the most resistant substrate, probably due to the relatively low number of nonreducing ends and short-length glucose oligomers susceptible to the exo-glucosidic activities of Mgam and Si, respectively. Density of a-1,6 diminished the digestibility of the substrates by WT mucosa. Corn amylopectin and all a-1,6 transglycosilated substrates showed lower digestibility than normal cornstarch, indicating that this is a structural feature affecting digestibility. However, waxy starch with high amylopectin content was very digestible by WT mucosa, suggesting that it contained easily digestible molecules, probably formed by large number of relatively small starch molecules with short branched chains. rhpAMY showed an intense synergism with the a-glucogenic activity of WT mucosa against most unpredigested substrates. Little or no change was observed in the a-glucogenesis of WT mucosa with LD and O2-5 when assayed in conjunction with rhpAMY, suggesting that molecules susceptible to further rhpAMY digestion were exhausted during the predigestion. Amylopectin, MD, and waxy corn starch (WX) showed some resistance to the synergic effect of rhpAMY, probably due to a limited number of internal regions susceptible to the endo-glucosidic activity of rhpAMY and the steric hindrance caused by the high density of a-1,6 linkages. All other substrates showed a 2-to 8-fold increment in a-glucogenesis by WT mucosa when assayed with rhpAMY. Surprisingly, starch substrates subject to a-1,6 linkage enrichment or a-1,4 chain shortening were markedly more sensitive to the synergic activities of rhpAMY and WT small intestinal mucosa (Table 3) . a-Glucosidase inhibition by acarbose. As mentioned earlier, acarbose is sometimes used to inhibit a-glucosidase activities in the management of type II diabetes (23) . To understand this inhibition in more detail, we examined acarbose inhibition of a-glucosidase activities in Mgam null and WT mice, as well as in mice from the CBA/CaJ strain ( Table 2 ). The Ki for maltose substrate in the WT homogenate was much lower than that of the Mgam null or CBA/CaJ strain mice (Fig, 6A-C , Table 2 ). The Ki for sucrose substrate was equal among the strains of mice and in the range of the Ki for maltose in the WT mouse. The Ki of acarbose for isomaltose and palatinose substrates was much higher than that for sucrose and did not differ among the strains of mice. In summary, acarbose was most inhibitory of Mgam and less inhibitory of Si.
Discussion
Validation of Mgam ablation. The ablation of the Mgam gene was found to be successful in 5 independent observations: 1) exon 2 was absent in DNA of the null mice; 2) the Lac-Z gene inserted into DNA was seen only in null villous enterocytes (25); 3) null mice did not have Mgam on Western blots; 4) in vivo starch digestion was reduced by half in the null mouse; and 5) assays of Mgam null jejunal homogenates revealed substantial reduction activities in all a-glucosidase substrates. The persistence of a-glucosidase activities in the null mouse was predictable because of the substrate overlapping of Mgam and Si mentioned earlier. As of this writing, we have maintained our Mgam null Sv/129 mice for 10 generations as homozygous gene lines without detectable metabolic or anatomic defects. Recent qPCR assays of mice from generation 10 confirmed that the breeding lines were completely conserved. An important conceptual contribution of our work is that a mouse strain with an absolute and exclusive deficiency of Mgam activity has allowed us to determine the relative roles of each intestinal a-glucosidic enzyme and detect their collaborative roles in the complex process of food starch digestion.
Phenotype of Mgam deficiency. There were no visible signs of gastrointestinal insufficiency in the null mice. Ablation of intestinal Mgam caused depression of a-glucosidic activity against all a-1,4 substrates assayed. Thus, the ability to generate free absorbable glucose from these substrates was markedly impaired in null mice. Maltase activity in null mice was only about one-third of the activity present in WT. In addition, the value of Km for maltose was .500% higher for null than for WT mice. Similarly, using varieties of starches and derived products as substrate and in the absence of rhpAMY, the a-glucosidic activity of null mice was always at least 95% lower than that of WT. Even in the presence of rhpAMY, the efficiency for a-glucogenesis of null mice remained much lower than that of WT mice. Thus, as a result of the Mgam KO, the null mice are severely deprived of starch derived glucose, particularly on low-starch diets where Si is ineffective and the missing Mgam, with a low Km, would be the only enzyme capable of releasing glucose by digestion of food starch.
Is Mgam a necessary enzyme for starch digestion? The null mouse jejunal and ileal mucosa had persistent a-glucosidase activities, but the Km of the residual activities in the null mice were 500% greater than WT. This was the consequence of slower Km of Si in null mice. To determine the in vivo significance of the changed activities in the small intestinal mucosa, a breath test of integrated starch digestion and oxidation was conducted in null and WT mice. A standard feeding of 13 C-LD was given by gavage, and breath enrichment of 13 CO 2 was measured at intervals. The WT mice with Mgam had a 2-fold larger increment in breath 13 CO 2 than null mice following the feeding. The use of 13 C-LD substrate, which was fully predigested by a-amylase, limits starch digestion to the mucosal a-glucosidase phase. This test confirmed the dominant role of Mgam in WT starch digestion and confirmed persistence of less active Si a-glucosidase in the null mouse.
Contribution of Si to starch digestion. The activities of Si were upregulated by 50% in null mice, probably by enhancement of the concentration of the Si protein molecules. To our knowledge, this is the first time that induction of Si activities has been documented as a direct result of Mgam deficiency. The upregulation of Si thus suggests existence of mechanisms for sensing total intestinal a-glucosidic activities or concentrations of produced glucose in blood or body tissues.
Contributions of human pancreatic AMY to starch digestion. Endo-glucosidic rhpAMY had a poor a-glucogenic activity but had an important synergic effect on mucosal enzymes by increasing the numbers of short glucose oligomer substrates for Mgam and Si exo-glucosidic activities. The endo-glucosidic activity of rhpAMY is inhibited by increased a-1,6 branching linkages or reduced length of a-1,4 chains.
Complexity of starch substrates. Our results revealed expected variations of glucose production from different food starches (Table 3 ) and several unifying conclusions were evident. The first is that ablation of Mgam reduces mucosal a-glucogenesis for all starches by ;20 fold. The second is that rhpAMY has little primary a-glucogenic activity but amplifies the mucosal a-glucogenic activities of Mgam null and WT mice from 1.5 to 4-fold. Prior full digestion with porcine pancreatic AMY to LD blocked all amplification of mucosal a-glucogenic activities by the luminal enzyme. LD is therefore an exclusive substrate for mucosal a-glucogenesis. The third conclusion is that the digestion of different food starches and starch products used varying combinations of the 6 a-glucogenic activities. Amylopectins and their hydrolytic products mostly are digested by WT jejunal activities (Mgam), whereas amylose and ''resistant'' starches 2 N, Normal cornstarch; Am, cornstarch amylose; Ap, cornstarch amylopectin; MD, maltodextrin; LD, limit dextrin; O2-5, equimolar mixture of glucose oligomers from G2 to G5; Wx, low amylose ''waxy'' starch; BBA, b-amylase treated normal cornstarch; BBA/TG, as in BBA followed by transglucosidase treatment; MA, maltogenic amylase treated normal cornstarch; MA/TG, as in MA followed by transglucosidase treatment.
are very dependant on luminal AMY amplification for full a-glucogenesis by WT mucosal activities.
Inhibition of starch digestion by acarbose. Studies of the inhibitory mechanism of acarbose on rhpAMY have revealed that it behaves as a mixed, competitive, and uncompetitive inhibitor. In this work, using WT, Mgam null, and CBA/CaJ mice with mixed Mgam and Si deficiency, we analyzed the differential inhibitory effects of acarbose on the mucosal a-glucogenic enzymes of these mouse strains. This strategy avoided the uncertainty caused by cross-contamination of Si and Mgam molecules that are present in samples purified by biochemical methods. We found differences of one order of magnitude among the Ki of acarbose on maltase activity measured in mucosal homogenates of WT (0.34 mmol/L), null (2.5 mmol/L), and CBA/Ca (13.3 mmol/L) mice. These differences suggest that Mgam is the most sensitive enzyme to the inhibitory effect of acarbose, whereas Si subunits require relatively high concentration of the inhibitor to inhibit their activity. The data obtained on catalytic properties of the enzymes and on acarbose inhibitory patterns suggest that, in vivo, this inhibitor impairs most of the a-glucogenic process from glucose oligomers digested by Mgam.
Significance of mouse Mgam null phenotype to human starch digestion. These studies of Mgam in the null and WT mouse are confirmatory of a parallel study of a-glucosidase activities in the human duodenal biopsies (16) . In the human study, the activities were immunoprecipitated from duodenal biopsy homogenates. By contrast, in this study the Mgam was ablated by KO technology. The immunoprecipitated human MGAM activity was inhibited by luminal concentrations of LD, MD, and G3, but SI activity was uninhibited. The MGAM inhibition was obscured in the Dahlqvist assay of human aglucosidases because of the 20-fold greater concentration of SI. The conclusion from our human studies was that MGAM primes intestinal glucogenesis and is important for low-starch diets and that SI sustains slower glucogenesis (16) . The present mouse studies confirm the differences of Mgam and SI Km reported in humans. The null mice had about one-half of the 13 C-LD fed breath 13 CO 2 enrichment of the WT. The breath test confirmed that the 5-to 10-fold greater mucosal activity of Mgam dominates normal mucosal starch digestion.
In summary, maltase-glucoamylase, present in the WT mice, regulates the total rate of starch a-glucogenesis. The absence of this enzyme in the mucosa of Mgam null mice reduced in vivo starch digestion by one-half. The in vitro mucosal sucraseisomaltase activity of the null mouse sustained total a-glucogenesis at half of the WT activity. The Km of jejunal a-glucogenesis null mice was 500% greater and total starch digestion was slowed by half, proving that upregulated mucosal Si cannot fully replace the ablated Mgam activities. The ablation of Mgam was mimicked by the a-glucosidase inhibitor acarbose, which was 700% more potent for Mgam activity of the WT mouse. a-Amylase was poorly a-glucogenic but was a synergistic amplifier of mucosal a-glucogenic activities. The a-amylase amplification was probably due to increased nonreducing ends following its internal hydrolysis of long-starch chains to short a-glucoside substrates. The a-amylase amplification was lost with a-limit-dextrin substrates. There are many known variations of food starch chemical composition. We investigated the integrated roles of Mgam, Si, and AMY with model starches. The interacting activities of the lumenal and mucosal enzyme varied with starch substrate composition, but Mgam remained as the dominant a-glucogenic activity. This enzyme interaction leads to the belief that the activities are not redundant but are part of an adaptive mechanism to allow small intestinal digestion of a broad range of food starch compositions.
